Compare MPLX LP (MPLX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs ResMed Inc. — how do they compare? MPLX LP trades at $56.35 (market cap $58.11B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: MPLX LP is the larger of the two by market cap, and MPLX LP pays the higher dividend (7.51%). Which is the better fit depends on your goals.
| MPLX | RMD | |
|---|---|---|
Market Cap | $58.11B | $31.89B |
Volume | 687,483 | 618,314 |
Sector | Energy | Health |
52-Week High | $60.51 | $277.88 |
52-Week Low | $47.80 | $182.82 |
Enterprise Value | $83.22B | $31.24B |
Dividend Yield | 7.51% | 1.16% |
Typical Hold Time | — | 51 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $56.12, down 1.63% with a bearish technical signal. The stock shows strong fundamentals with a 12.33 P/E ratio, 40.45% net income margin, and consistent dividend payments. Recent earnings show mixed results with Q4 2025 beating expectations but subsequent quarters missing targets. Analyst consensus remains strongly bullish with 19 buy ratings and a $63.80 price target, representing 13.7% upside potential from current levels.
The outlook remains positive given MPLX's resilient midstream business model with fee-based revenues insulating it from energy price volatility. Key risks include potential energy market downturns and execution challenges in the Permian Basin expansion. The company's strong cash flow generation supports its 8% dividend yield, making it attractive for income investors seeking energy exposure with reduced commodity price sensitivity.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
